Navigation Links
Migraine in Medical Technology

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

... development plans for AZ-104 for the treatment of migraine headaches." About Acute migraine Headaches According to the National ... in the United States have been diagnosed with migraine ...

Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura

... in Denmark of tonabersat in the prevention of migraine with aura. The median number of aura attacks was ... in favor of tonabersat compared with placebo. migraine with aura affects around 30 percent of migraine sufferers and is a type ...

Swedish in Seattle to Study Connections Between Preeclampsia and Migraine

... her co-investigator Sheena Aurora, M.D., a migraine specialist with the Swedish Pain and Headache ... pre-gestational history of migraines and migraine symptoms during early pregnancy are associated ... cause of maternal and infant illness and death. migraine is a common chronic-episodic disorder ...

Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008

... that COL-144 was safe and effective in relieving migraine headaches. COL-144 is a first-in-class Neurally ... The randomized, double-blind study evaluated 130 migraine patients. Patients were not on prophylaxis and ... 20 minutes as first-line treatment of an acute migraine attack. The primary end-point parameter was ...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

... AZ-001 to treat patients suffering from acute migraine headaches. Alexza requested an end of Phase 2 ... AZ-104 to treat patients suffering from acute migraine headaches. AZ-104 is a lower dose version of ... allowed to conduct the first patient study in migraine patients, the Phase 2a proof-of-concept trial ...

MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion

... study of healthy volunteers. "Asthma and migraine have a high incidence of co-morbidity, so it ... has a long history of use as a safe and effective migraine treatment. Many headache specialists consider DHE ... to be the standard of care in treating chronic migraine and debilitating migraines that last more than 72 ...

MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine

... has the potential to be a first-line therapy for migraine patients," said Timothy S. Nelson, president and ... has a long history of use as a safe and effective migraine treatment. Many headache specialists consider DHE ... to be the standard of care in treating chronic migraine and debilitating migraines that last more than 72 ...

Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel

... a 306-patient Phase IIb clinical trial in acute migraine headache. Specifically, tezampanel demonstrated ... "This is our second positive study in acute migraine with tezampanel," said Neil Kurtz, M.D., ... a number of diseases and disorders. These include migraine and other forms of chronic pain such as ...

MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting

... study, MAP0004 stimulated receptors that relieve migraine at levels comparable to IV DHE, but did not ... in a Phase 2 study is also important because migraine and asthma are frequently co-morbid conditions." ... the MAP0004 program, including: -- Newer Acute migraine Specific Drugs May Provide Improved ...

Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting

... device would help an estimated 39 percent of migraine sufferers. The device, about the size and ... ticket to help relieve the pain of chronic migraine sufferers. Occipital nerve stimulation, in which ... has been shown to help 40 percent of near-daily migraine sufferers who don't have success with ...

TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate

... discuss the opportunity of treating chronic pain, migraine and muscle spasticity through the inhibition of ... the brain as a target for acute and prophylactic migraine therapy. He is a member of the American ... clearly a promising approach for the treatment of migraine and other conditions." TorreyPines ...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

... loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting ... Reduces Headache Pain in Patients Having an Acute migraine Attack", is scheduled for Friday, June 27, 2008 ... (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for ...

ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment

... Show Significant Improvements With ROX-828 In migraine Pain And Related Symptoms For Up to 48 ... one dose of study drug when they experienced a migraine attack. "While in-depth analysis of the data is ... may offer a meaningful advantage for patients." migraine is a common recurring condition marked by severe, ...

Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine

... provided significantly more patients migraine pain relief compared to sumatriptan 85 mg ... has approved Treximet for the acute treatment of migraine attacks with or without aura in adults. Treximet is the first and only migraine product designed to target multiple mechanisms ...

Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status

... is being developed for the acute treatment of migraine headaches. Alexza reported positive results from ... is being developed for the acute treatment of migraine headaches. AZ-104 is a lower dose version of ... (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for ...

Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache

... of AZ-104 (Staccato(R) loxapine) in patients with migraine headache. migraine is a debilitating, yet common neurological ... designed to evaluate the treatment of a single migraine attack in each of ...

TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds

... II clinical trial of tezampanel in acute migraine headache. As reported last October, ... utility of tezampanel for indications beyond migraine and chronic pain. -- Complete the ... for tezampanel and NGX426 as treatments for migraine headache and other chronic pain and non-pain ...

Multiple Dose Clinical Trial of TorreyPines Therapeutics' Tezampanel Demonstrates Compound is Safe and Well-Tolerated

... clinical trial of tezampanel in 306 patients with migraine met its primary endpoint for pain relief at two ... the transmission of pain signals that lead to migraine headaches. The blockade of similar receptors in ... prove to be safe and effective treatments for migraine and other pain conditions as well as non-pain ...

Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status

... is being developed for the acute treatment of migraine headaches. Alexza reported positive results from ... is being developed for the acute treatment of migraine headaches. In December 2007, Alexza ... clinical trial with AZ-104 in patients with migraine headache. The Phase 2a clinical trial was an ...

Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients

... placebo-controlled study in approximately 160 migraine patients with or without aura. Three doses ... during the first quarter of 2008." About Acute migraine Headaches According to the National Headache ... in the United States have been diagnosed with migraine ...

Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics' Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache

... to Initiate Phase IIa Study of NGX426 in Acute migraine in First Half of 2008 - ... NGX426 also may be effective in treating acute migraine headache. TorreyPines Therapeutics plans to initiate a Phase IIa study of NGX426 in acute migraine in the first half of 2008. "These findings with ...

A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females

... Placebo-Controlled Dose-Escalating Study in migraine patients was successfully completed. This event ... of MTR106 in female patients suffering from migraine without aura. The study population consisted of ... 22-57 years of age. The average duration of migraine attacks was 16.6 +/- 10 hours with a frequency of ...

Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache

... trial for the treatment of a single, acute migraine attack. In the study, which evaluated tezampanel ... disability and a composite score of core migraine symptoms at two and four hours post-dose that ... in order to initiate a Phase III program in acute migraine in the second half of 2008. In this trial, all ...

Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego

... (Nasdaq: TPTX ) for the treatment of acute migraine headache, was shown in an independent study to be ... CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, ... the potential for tezampanel as a treatment for migraine and other pain indications, the potential for ...

TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel

... Currently in Phase IIb Clinical Trial for Acute migraine - LA JOLLA, Calif., Aug. 27 ... development of tezampanel for the treatment of migraine as well as allow TorreyPines to consider ... Officer of TorreyPines. "Our Phase IIb trial in migraine has completed enrollment and we are on track to ...

TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache

... trial of tezampanel for the treatment of acute migraine headache. Tezampanel is an AMPA/kainate (AK) ... new and promising alternative to current migraine treatments. The clinical trial is a ... enrollment of 300 patients suffering a single migraine attack, with or without aura. Patients are ...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

... Alexza is developing AZ-104 to treat patients suffering from acute migraine headaches. AZ-104 is a lower dose version of AZ-004. In January 2009, ... Both product candidates are being developed for the acute treatment of migraine headache. AZ-002 ( Staccato alprazolam) has completed Phase 1 testing ...

Study Confirms: Your Hidden Food Allergies Are Making You Fat

... benefit of The ALCAT Test to help chronic symptoms such as obesity, IBS, migraine and arthritis. DEERFIELD BEACH, Fla., April 6 /PRNewswire/ -- Medical ... Food sensitivities often provoke delayed and chronic symptoms, like IBS, migraine and arthritis, that are not as obvious as the dramatic and immediate onset ...

TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel

... the potential to treat a number of diseases and disorders. These include migraine and other forms of chronic pain such as neuropathic pain, muscle ... analgesic and the potential for tezampanel and NGX426 as treatments for migraine and other forms of chronic pain such as neuropathic pain, muscle ...

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

... and U01 HL65962 and American Heart Association grant 0940116N; by the German Federal Ministry of Education and Research (01GI9909/3), by the German migraine & Headache Society (DMKG), and by unrestricted grants of equal share from Astra Zeneca, Berlin Chemie, Boots Healthcare, Glaxo-Smith-Kline, ...

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

... neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; ...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

... neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; ...

Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments

... neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; ...

Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration

... neuralgia; PERCOCET(R) and PERCODAN(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; ...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

... Company has completed its end-of-Phase 2 meeting with the FDA for AZ-001 (Staccato prochlorperazine), which is intended for the acute treatment of migraine headache, and it has advanced AZ-104 (Staccato loxapine) to Phase 2 testing. Product candidates that have completed Phase 1 testing are AZ-003 ...

Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures

... solutions that improve neurological health. The company currently markets products for Alzheimer's disease, epilepsy and acute and preventive migraine treatment. In conjunction with internal and external research partners, Ortho-McNeil Neurologics continues to explore new opportunities to develop ...

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

... or bipolar disorder patients, has completed one Phase 3 clinical trial and the second Phase 3 clinical trial ongoing. For the acute treatment of migraine headaches, AZ-001 (Staccato prochlorperazine) has completed Phase 2 testing and AZ-104 (Staccato loxapine) is in Phase 2 testing. Product candidates ...

FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months

... as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome. TOPAMAX(R) is indicated in adults for the prophylaxis of migraine headache. Important Safety Information: Serious risks associated with TOPAMAX include lowered bicarbonate levels in the blood resulting in an ...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

... prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product ...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

... prochlorperazine) for the acute treatment of migraine headaches has completed Phase 2 testing. AZ-104 (Staccato loxapine) for the acute treatment of migraine headaches and AZ-002 (Staccato alprazolam) for the acute treatment of panic attacks associated with panic disorder are in Phase 2 testing. Product ...
Other Contents
(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... the house fly genome for the first time, revealing ... insect that thrives in pathogen-rich dung piles and garbage ... journal Genome Biology , will increase understanding of ... quickly adapt to resist insecticides, which could lead to ... carry and transmit more than 100 human and animal ...
(Date:10/14/2014)... A team of scientists led by researchers at ... the University of Miami Miller School of Medicine ... genetic pathway underlying bipolar (manic depressive) disorder, a ... treating bipolar affective disorder, as well as depression ... findings, published online this week in Nature ...
Breaking Biology News(10 mins):Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2House fly genome reveals expanded immune system 2Rare genetic disease protects against bipolar disorder 2Rare genetic disease protects against bipolar disorder 3
(Date:10/20/2014)... October 20, 2014 Principle Business Enterprises, ... pride in manufacturing top-of-the-line absorbent products. The company ... its most popular brand, Tranquility® Premium Protection absorbent products. ... new website, gave its packaging a new look, and ... brand message to the public. , The new website, ...
(Date:10/20/2014)... Succeed is proud to announce that they ... in the Every Body Walk! campaign by Kaiser ... that encourages workers to be more active outside of the ... concluded at the end of September, was a friendly competition ... areas. Participating companies gave their staff pedometers and each ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
(Date:10/20/2014)... 2014 Do you ever feel difficulty ... a wonderful app Metassessor for teachers, specialists and parents. ... helped its client “Intervention Development LLC” to launch Metassessor ... designed for iOS 4.3 or later and is Compatible ... optimized for iPhone 5. It is now available on ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
Other TagsOther Tags